Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
25.97
-0.18 (-0.69%)
At close: Aug 13, 2026, 4:00 PM EDT
26.48
+0.51 (1.96%)
After-hours: Aug 13, 2026, 7:58 PM EDT
Company Description
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
The company was incorporated in 2024 and is headquartered in San Francisco, California.
Braveheart Bio, Inc.
| Country | United States |
| Founded | 2024 |
| IPO Date | Aug 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Travis Murdoch |
Contact Details
Address: One Letterman Drive, Building A San Francisco, California 94129 United States | |
| Phone | 415 707 6312 |
| Website | braveheart.bio |
Stock Details
| Ticker Symbol | BRVE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2131524 |
| CUSIP Number | 10567X101 |
| ISIN Number | US10567X1019 |
| Employer ID | 99-2981994 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Travis Murdoch, M.D. | Chief Executive Officer, President and Director |
| Michele Anderson | Chief Development Officer |
| J. Paul Rickey | Chief Financial Officer |
| Tyler Chavez | Chief Business Officer |
| Marc Evanchik, M.S. | Chief Scientific Officer |
| Emil deGoma | Chief Medical Officer |
| Christopher Viehbacher | Chairman of the Board |
| Vineeta Agarwala, M.D., Ph.D. | Director |
| Jasper Bos, Ph.D. | Director |
| Erez Chimovits, M.B.A., M.Sc. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2026 | 8-K | Current Report |
| Aug 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 6, 2026 | 424B4 | Prospectus |
| Aug 6, 2026 | CERT | Certification by an exchange approving securities for listing |
| Aug 5, 2026 | EFFECT | Notice of Effectiveness |
| Aug 5, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Aug 3, 2026 | 8-A12B | Registration of securities |
| Jul 30, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 15, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 8, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |